News & Events

Home | News | Ki-67 algorithm from Zeno Pathology in clinical study

Ki-67 algorithm from Zeno Pathology in clinical study

Together with Stacey Joosten et al. from the Netherlands Cancer Institute, WSK Medical collaborated on the clinical study “IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women”.

In this study, we compared pathologist assessed IHC-based Ki67 in samples from pre- and postmenopausal women in a neo-adjuvant, endocrine therapy focused trial and compared these results – among others – with our Artificial Intelligence (AI) Ki-67 algorithm that is part of our CE certified digital pathology solution Zeno Pathology.

The results from this study showed the added value of using AI in collaboration with doctors to assist in decision-making and analysis of complex, clinical data. The paper can be found here.

Share –

Related articles

Zeno AI featured article on Open Access Government

The successful launch and implementation of Zeno AI, the first of its kind real-time AI solution for early laryngeal (throat) cancer detection for ENT-surgeons, was the subject of an article published by Open Access Government.


World Summit AI – Exhibiter – 12-13th of October in Amsterdam

What is World Summit AI?

The world’s leading and largest AI summit gathers the global AI ecosystem of Enterprise, Big Tech, Startups, Investors and Science, the brightest brains in AI as speakers every October in Amsterdam to tackle head-on the most burning AI issues and set the global AI agenda. You can find more information here.


WSK Medical part of the EMPAIA consortium

WSK Medical has signed a partnership agreement with the EMPAIA consortium. With this partnership, WSK Medical aims to add knowledge to the consortium about the development and deployment of AI solutions for early cancer detection.

Demo //

Book a demo

Want to learn more about our solutions?

Our website only uses essential cookies. These cookies are used to make the website function properly. By continuing your visit on our website, you understand this. All our privacy related matters can be found in our privacy policy.